BR112014027957A8 - métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer" - Google Patents
métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer"Info
- Publication number
- BR112014027957A8 BR112014027957A8 BR112014027957A BR112014027957A BR112014027957A8 BR 112014027957 A8 BR112014027957 A8 BR 112014027957A8 BR 112014027957 A BR112014027957 A BR 112014027957A BR 112014027957 A BR112014027957 A BR 112014027957A BR 112014027957 A8 BR112014027957 A8 BR 112014027957A8
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- cell
- graft
- allogeneic
- infusion
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title abstract 8
- 238000001802 infusion Methods 0.000 title abstract 6
- 210000004698 lymphocyte Anatomy 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001052 transient effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 239000012636 effector Substances 0.000 abstract 4
- 210000003289 regulatory T cell Anatomy 0.000 abstract 4
- 230000002459 sustained effect Effects 0.000 abstract 4
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 230000005809 anti-tumor immunity Effects 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 2
- 230000003750 conditioning effect Effects 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 238000011476 stem cell transplantation Methods 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
abstract of the invention the invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of cd4+ t cell help for endogenous, tumor-reactive cd8+ t cells. depletion of cd8+ t cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. removal of regulatory t cells from the infused population may augment the ability of non-regulatory t cells to provide help for endogenous effectors of anti-tumor immunity. allogeneic t cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature t cells. in the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector t cells derive from the host. ********************************* tradução do resumo resumo patente de invenção: "métodos e composições para infusão de populações selecionadas de enxertia transiente de linfócitos alogênicos para tratamento de câncer". a invenção fornece métodos e composições para administração de linfócitos alogênicos como uma fonte exógena de auxílio de células t cd4+ para células t cd8+ endógenas reativas a tumor. a depleção de células t cd8+ da infusão de linfócito de doador reduz o risco de doença enxerto contra hospedeiro e enxertia sustentada. a remoção de células t regulatórias da população infundida pode aumentar a habilidade de células t não regulatórias para fornecer auxílio para efetores endógenos de imunidade anti-tumoral. a terapia de célula t alogênica é tipicamente dada no contexto de transplante de célula-tronco alogênica, em que o paciente recebe um condicionamento altamente imunosupressivo sucedido por uma infusão de um enxerto de célula-tronco que contém populações não selecionadas de células t maduras. no tratamento descrito aqui, o enxerto é modificado para minimizar a possibilidade de enxertia sustentada de célula de doador, e as células t efetoras antitumorais são derivadas do hospedeiro. 23020494v1 1/1 23020494v1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644126P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/032129 WO2013169386A1 (en) | 2012-05-08 | 2013-03-15 | Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014027957A2 BR112014027957A2 (pt) | 2017-06-27 |
| BR112014027957A8 true BR112014027957A8 (pt) | 2018-01-16 |
Family
ID=49551134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014027957A BR112014027957A8 (pt) | 2012-05-08 | 2013-03-15 | métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer" |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9931359B2 (pt) |
| EP (2) | EP3144008B1 (pt) |
| CN (1) | CN104394877B (pt) |
| AU (1) | AU2013260132B2 (pt) |
| BR (1) | BR112014027957A8 (pt) |
| CA (2) | CA3132353A1 (pt) |
| DK (1) | DK2846816T3 (pt) |
| ES (1) | ES2607148T3 (pt) |
| WO (1) | WO2013169386A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CN106687125B (zh) | 2014-03-12 | 2021-12-14 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR102666781B1 (ko) * | 2015-05-12 | 2024-05-20 | 메모리얼 슬로안 케터링 캔서 센터 | T 세포 요법에 의한 엡스타인-바 바이러스 관련 림프증식성 장애의 치료 방법 |
| SG10201913620QA (en) * | 2015-05-28 | 2020-03-30 | Kite Pharma Inc | Diagnostic methods for t cell therapy |
| SG10201913613SA (en) | 2015-05-28 | 2020-03-30 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| WO2017048822A1 (en) * | 2015-09-14 | 2017-03-23 | Baylor College Of Medicine | IMMUNE STIMULATORY FUNCTION AND ANTI-TUMOR ACTIVITY OF TGF-β1 PRIMED MYELOID DERIVED SUPPRESSOR CELLS (MDSC) |
| US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
| SG11202002728VA (en) | 2017-10-03 | 2020-04-29 | Juno Therapeutics Inc | Hpv-specific binding molecules |
| WO2019084008A2 (en) * | 2017-10-23 | 2019-05-02 | The Regents Of The University Of California | LYMPHOCYTES T REGULATORS PLZF + FOR THE CONTROL OF INFLAMMATION |
| WO2019084258A1 (en) * | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF CONDITIONING BASED ON ANTI-CD45 AND USES THEREOF IN COMBINATION WITH GENETICALLY MODIFIED CELL THERAPIES |
| PE20201345A1 (es) | 2018-04-05 | 2020-11-25 | Juno Therapeutics Inc | Receptores de celulas t, y celulas disenadas que expresan los mismos |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| CA3166961A1 (en) * | 2020-02-10 | 2021-08-19 | Ephraim Joseph Fuchs | Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells |
| CN111537424B (zh) * | 2020-04-26 | 2022-10-28 | 北京市神经外科研究所 | 基于外周血细胞评估脊髓胶质瘤患者预后性的系统 |
| CN111643525A (zh) * | 2020-06-16 | 2020-09-11 | 济宁医学院 | 引发免疫排斥反应在肿瘤治疗中的应用及其方法 |
| CN114452388A (zh) * | 2022-03-07 | 2022-05-10 | 北京大学第一医院 | 一种降低血循环系统中eb病毒拷贝数的方法和系统 |
| WO2024073529A1 (en) * | 2022-09-29 | 2024-04-04 | Iyuda Therapeutics, Llc | Methods and compositions for localized production and delivery of biological molecules |
| US20240197816A1 (en) * | 2022-12-08 | 2024-06-20 | Novmetapharma Co., Ltd. | Composition and method for prolong survival of transplant and recipient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
| CA2280156C (en) | 1997-02-11 | 2007-10-02 | William H. Hildebrand | Class i sequence based typing of hla-a, -b, and -c alleles by direct dna sequencing |
-
2013
- 2013-03-15 WO PCT/US2013/032129 patent/WO2013169386A1/en active Application Filing
- 2013-03-15 CN CN201380030373.7A patent/CN104394877B/zh active Active
- 2013-03-15 BR BR112014027957A patent/BR112014027957A8/pt not_active Application Discontinuation
- 2013-03-15 ES ES13788469.8T patent/ES2607148T3/es active Active
- 2013-03-15 CA CA3132353A patent/CA3132353A1/en active Pending
- 2013-03-15 DK DK13788469.8T patent/DK2846816T3/en active
- 2013-03-15 EP EP16190858.7A patent/EP3144008B1/en active Active
- 2013-03-15 US US14/398,724 patent/US9931359B2/en active Active
- 2013-03-15 EP EP13788469.8A patent/EP2846816B1/en active Active
- 2013-03-15 AU AU2013260132A patent/AU2013260132B2/en active Active
- 2013-03-15 CA CA2872643A patent/CA2872643C/en active Active
-
2018
- 2018-03-28 US US15/939,059 patent/US20180280439A1/en not_active Abandoned
-
2021
- 2021-11-12 US US17/525,714 patent/US20220143090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150132290A1 (en) | 2015-05-14 |
| US20180280439A1 (en) | 2018-10-04 |
| EP2846816A1 (en) | 2015-03-18 |
| EP3144008B1 (en) | 2018-01-17 |
| EP2846816B1 (en) | 2016-09-28 |
| CN104394877A (zh) | 2015-03-04 |
| DK2846816T3 (en) | 2017-01-16 |
| EP2846816A4 (en) | 2015-11-04 |
| CA3132353A1 (en) | 2013-11-14 |
| US20220143090A1 (en) | 2022-05-12 |
| WO2013169386A1 (en) | 2013-11-14 |
| ES2607148T3 (es) | 2017-03-29 |
| CA2872643A1 (en) | 2013-11-14 |
| EP3144008A1 (en) | 2017-03-22 |
| AU2013260132A1 (en) | 2014-11-27 |
| CN104394877B (zh) | 2017-11-28 |
| CA2872643C (en) | 2021-11-16 |
| AU2013260132B2 (en) | 2017-12-14 |
| US9931359B2 (en) | 2018-04-03 |
| BR112014027957A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027957A8 (pt) | métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer" | |
| Abu Eid et al. | Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition | |
| Castagna et al. | Donor lymphocyte infusion after allogeneic stem cell transplantation | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| MX2016010923A (es) | Metodo para generar celulas t compatibles para el trasplante alogenico. | |
| Macciò et al. | Blocking inflammation to improve immunotherapy of advanced cancer | |
| CL2020003319A1 (es) | Receptores del factor de crecimiento quiméricos | |
| GB2500161A (en) | Enhancement of allogeneic hematopoietic stem cell transplantation | |
| Composto et al. | Peritoneal T lymphocyte regulation by macrophages | |
| Zhang et al. | Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4+ Foxp3+ Treg cell accumulation | |
| Patel et al. | Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| Xue et al. | WT1-targeted immunotherapy of leukaemia | |
| Chen et al. | ECDI-fixed allogeneic splenocytes combined with α1-antitrypsin prolong survival of rat renal allografts | |
| Shafeghat et al. | Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view | |
| Vyas et al. | Cell-based therapies in vascularized composite allotransplantation | |
| MX2022012522A (es) | Composiciones y metodos para potenciar la activacion y la actividad citolitica de linfocitos t cd8+ a traves de la interrupcion del complejo saga (spt-ada-gcn5-acetiltransferasa). | |
| WO2020215013A1 (en) | Tolerogenic dendritic cells and uses thereof | |
| Bao et al. | Adaptive transfer of B10 cells: a novel therapy for chronic rejection after solid organ transplantation | |
| Stauss et al. | Exploiting alloreactivity for tumour immunotherapy. | |
| Spyridonidis et al. | Hypomethylating Agents Induce FOXP3 Negative HLA-G Expressing Immunoregulatory T Cells | |
| Brandstadter et al. | Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity | |
| Cheng | Cellular Therapeutics-Based Strategies for Inducing Donor-Specific Tolerance to Vascularized Composite Allotransplants | |
| Humblet et al. | Regulatory T cells fulfil their promise? | |
| Sharma | Regulatory T Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |